-SCY-635 shows potential as an Immune Acting Antiviral to augment current treatments-
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- SCYNEXIS, Inc. today announced that the results of a Phase 2a study of lead candidate SCY-635 for the treatment of the hepatitis C virus (HCV) will be the subject of an oral presentation at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place from November 9-13 in Boston, Massachusetts. The Phase 2a study tested SCY-635 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV) in a difficult to treat population of HCV genotype 1 patients.
The presentation, titled “Short Duration Treatment with SCY-635 Restores Sensitivity to Peg-IFN/RBV in Difficult to Treat, IL28B TT/CT, HCV Genotype 1 Patients” will be given by Dr. Andrew J. Muir, lead investigator of the study, beginning at 4:45 ET on November 11th in room 210 at the Hynes Convention Center.
SCY-635 has demonstrated the potential to play an important role in the reversal of immune exhaustion, or as an Immune Acting Antiviral, in difficult to treat patients with HCV.
The trial was a randomized, placebo-controlled, double-blind study with the primary objective of evaluating the effect of treatment with SCY-635 in combination with PegIFN α-2a and RBV on HCV viral replication in treatment-naive subjects with chronic genotype 1 infection who have an IL28B genotype of C/T or T/T.
About HCV and Therapeutic Need
The World Health Organization estimates that about 3% of the world’s population is infected with HCV and that there are more than 170 million chronic carriers who are at risk of developing liver cirrhosis and/or liver cancer. The recent introduction of protease inhibitors (Telaprevir and Boceprevir) has improved the response rate to interferon/ribavirin based therapy, however treatment options for difficult to treat (non-CC), HCV genotype 1a infected patients remain sub-optimal. Resistance issues, serious side effects, including black box labeling, and a significant population of patients who are contraindicated to interferon based therapy have created an urgent demand for new anti-HCV agents that can reduce or eliminate interferon based regimes.
While the majority of antiviral research remains focused on viral targets such as protease and polymerase enzymes, therapies such as SCY-635 that are based on immunomodulation to counteract viral immune evasion could be of great therapeutic value. The addition of SCY-635 to the repertoire of currently approved HCV therapies could breathe new life into the future of these treatment regimens for difficult to treat patients for whom these compounds have not been previously effective.
SCY-635 is novel oral Cyclophilin inhibitor in Phase 2 studies for the treatment for Hepatitis C (HCV) and in preclinical studies for the treatment of Hepatitis B (HBV). Studies to date have demonstrated that SCY-635 is unique in that it plays a dual role as a synergistic Direct Acting Antiviral (DAA) and a stimulator of the host immune system (Immune Acting Antivirals or IAAs).
SCYNEXIS delivers innovative solutions to solve the toughest problems in drug discovery and development for our pharmaceutical, global health and life science partners. We have successfully delivered preclinical and clinical drug candidates to our customers across all major therapeutic indications and have developed our own proprietary cyclophilin inhibitor programs for the treatment of a broad range of diseases, including HCV, HBV and inflammation. www.scynexis.com
Alissa Maupin, +1-919-206-7246
Marketing & Communications Manager
MacDougall Biomedical Communications
Christian Nielsen, +1-781-235-3060
Source: SCYNEXIS, Inc.